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Modifier geneCerebellar ataxias are progressive neurodegenerative disorders characterized by atrophy of the cerebellum lead-
ing tomotor dysfunction, balance problems, and limb and gait ataxia. These include among others, the dominant-
ly inherited spinocerebellar ataxias, recessive cerebellar ataxias such as Friedreich's ataxia, and X-linked
cerebellar ataxias. Since all cerebellar ataxias display considerable overlap in their disease phenotypes, common
pathological pathways must underlie the selective cerebellar neurodegeneration. Therefore, it is important to
identify the molecular mechanisms and routes to neurodegeneration that cause cerebellar ataxia. In this review,
we discuss the use of functional genomic approaches including whole-exome sequencing, genome-wide gene
expression profiling, miRNA profiling, epigenetic profiling, and genetic modifier screens to reveal the underlying
pathogenesis of various cerebellar ataxias. These approaches have resulted in the identification of many disease
genes, modifier genes, and biomarkers correlating with specific stages of the disease. This article is part of a Spe-
cial Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The cerebellar ataxias are a group of clinically homogeneous and ge-
netically heterogeneous neurodegenerative disorders, all characterized
by progressive atrophy of the cerebellum and a clear loss of Purkinje
cells, leading to impairment of motor function, balance, gait and speech.
The most prominent clinical feature is cerebellar ataxia, which is often
associated with additional neurological manifestations such as pyrami-
dal, extrapyramidal and cognitive dysfunction. Given the clear overlap
in disease phenotypes and the various modes of presentation of cere-
bellar ataxia, making a correct diagnosis is challenging. The disease in-
heritance patterns can be autosomal dominant, recessive, X-linked or
even mitochondrial in a few ataxia syndromes. The precise number of
cerebellar ataxias is unknown, but at least 37 dominantly inherited
spinocerebellar ataxias (SCAs), 20 recessive ataxias and a few X-linked
and mitochondrial inherited forms of cerebellar ataxia are known
[1–3]. Taken together, all ataxias have an estimated prevalence of
15–20:100,000 [4]. Despite all the known disease-causing genes,
around 30% of all cerebellar ataxia patients remain genetically
undiagnosed.nome to Function.
versity of Groningen, University
gen, TheNetherlands. Tel.:+31In addition to a genetically heterogeneous background, a broad
range of mutation types have been identified that contribute to the
complex etiology of the cerebellar ataxias. A large number are caused
by coding polyglutamine (CAG; polyQ) repeat expansions, or non-
coding CTG, CAG, and GAA repeats, but cerebellar ataxias caused by
penta- or hexanucleotide repeat expansions have also been reported
[5]. Missense mutations, deletions, duplications, splice and truncating
mutations have also been identified. All ataxia genes in dominant cere-
bellar ataxias seem functionally different but operate in shared path-
ways including protein misfolding and aggregation, impairment of
the protein quality control system, dysregulation of gene transcription,
RNA toxicity, and alterations in synaptic transmission [6,7]. On the
other hand, alterations in mitochondrial functioning, DNA repair effi-
ciency, synaptic transmission, chaperone activity, and metabolic func-
tioning underlie recessive cerebellar ataxias [2]. The main challenge
for clinicians and researchers is the development of a therapy that can
intervenewith these various diseasemechanisms, as there is no therapy
that slows progression or prevents these diseases from occurring.
In this review, we discuss how advances in technology allow us
to reveal the whole-exome variation, and the whole-genome tran-
scriptome or epigenome in human, cell and animal models of cerebellar
ataxia (overview in Table 1). To get more in-depth information on the
underlying genetic variation in the genome and gene expression associ-
ated with cerebellar ataxia, work using next generation sequencing,
gene expression profiling, miRNA profiling and methylation profiling
is reviewed. An additional method to examine the active transcriptome
is ribosomal trapping, however, to date, this technique is not utilized in
Table 1
Overview of all cerebellar ataxias used in this review.
Disease Gene Mutation type Reference
Conventional mutations
SCA5 SPTBN2 Missense [17]
SCA19/22 KCND3 Missense/in frame deletion [8,9]
SCA28 ALG3L2 Missense [24]
SCA35 TGM6 Missense [7]
SCA26 eEF2 Missense [10]
Adult-onset, recessive spinocerebellar ataxia
with psychomotor retardation
SYT14 Missense [11]
Early-onset cerebellar neurodegeneration UCHL1 Missense [12]
Recessive cerebellar ataxia with spasticity GBA2 Missense [13]
X-linked cerebellar ataxia PMCA3 Missense [14]
X-linked cerebellar ataxia GJB1 Missense [15]




SCA1 ATXN1 CAG expansion [27,28,30,36,62,67]
SCA2 ATXN2 CAG expansion [29]
SCA3 ATXN3 CAG expansion [31,64,65]
SCA7 ATXN7 CAG expansion [28,32,43,66]
SCA17 TBP CAG expansion [68]
GAA repeat expansion
Friedreich's ataxia FXN GAA expansion [22,23,25]
2031C.J.L.M. Smeets, D.S. Verbeek / Biochimica et Biophysica Acta 1842 (2014) 2030–2038ataxia research, and will not be discussed in this review. We examine
how functional genomics leads to identification of the routes to neuro-
degeneration and improves our understanding of the pathogenesis of
cerebellar ataxia.
2. Identification of novel cerebellar ataxia genes by next
generation sequencing
The way in which genes for Mendelian disorders such as cerebellar
ataxia are identified has changed significantly with the introduction of
genome-wide genotyping and next generation sequencing. The tradi-
tional approach, first mapping the disease gene using linkage analysis
in large pedigrees followed by candidate gene Sanger sequencing, was
time consuming, labor intensive, and had low success rates. Further-
more, large pedigreeswere rarely available for late age of onset diseases
like the dominant cerebellar ataxias, the numbers of genetic markers
were relatively limited, and the identified linkage intervals were large
and containedmany genes, which affected the time and costs necessary
to study a single family.
Genome-wide genotype analysis using arrays containing up to a
million single-nucleotide-polymorphisms (SNPs) to pinpoint candidate
regions in the genome and whole-exome sequencing or sequencing of
custom captured genomic regions to unravel millions of coding DNA
fragments at the same time have had a great impact on disease gene
identification in Mendelian disorders, as these approaches require
smaller families, and have shorter turn-around times. In contrast to ear-
lier methods, this approach does not always lead to the identification of
the disease gene because approximately 20,000 variants will be identi-
fied per individual per sequence run, and themutation could be located
in the non-coding part of the genome. To be able to identify the causal
variation, proper validation is needed by co-segregation analysis within
additional family members (if available) and by the generation of func-
tional disease models.
The first success story using this work scheme for dominant cere-
bellar ataxia was reported by Wang et al. [8], who identified heterozy-
gous mutations in TGM6 encoding transglutaminase 6 to underlie
SCA35. Similarly, the voltage-gated potassium channel KCND3 was
identified as the SCA19/22 disease gene [9,10], and heterozygousmuta-
tions in eEF2 encoding for Eukaryotic Translation Elongation Factor 2,
were proven to cause SCA26 [11]. The recessive ataxias are very suitablefor homozygositymapping using high-density SNP arrays in affected in-
dividuals, whichpinpoints a potential causal variant in oneof the homo-
zygous genomic regions, followed by whole-exome sequencing of two
affected family members. Recently, synaptotagmin 14 (SYT14) was
linked to adult-onset, recessive spinocerebellar ataxia with psychomo-
tor retardation [12], ubiquitin carboxyl-terminal esterase L1 (UCHL1)
to early-onset cerebellar neurodegeneration [13], and glucosidase beta
2 (GBA2) to recessive cerebellar ataxia with spasticity [14]. Additionally,
sequencing using an X-chromosome capturing array or X-chromosome
haplotype analysis followed by whole-exome sequencing identified
two novel X-linked ataxia disease genes, PMCA3 and GJB1, encoding
for ATPase Ca2+ transporting plasma membrane 3 and gap junction
protein beta 1, respectively [15,16].
Sequencing of RNA transcripts ismainly applied to count their abun-
dance, but can also be used to identify novel splice variants and causal
variations. As yet, no successes have been reported for humans. How-
ever, genome-wide RNA sequencing facilitated the identification of
the disease gene, beta-spectrin (SPTBN), for canine cerebellar cortical
degeneration [17], previously associatedwith SCA5 (SPTBN2) [18]. Like-
wise, a mutation in U2 snRNA (RNU2) was shown to cause global dis-
ruption of alternative splicing and cerebellar neurodegeneration and
ataxia in mice [19].
Over the last three years, nine novel cerebellar ataxia genes have
been identified using a combination of gene mapping and next gen-
eration sequencing. These findings emphasize the genetic heterogene-
ity of these disorders and the complexity of the underlying disease
etiology. The Gene Annotation Tool to Help Explain Relationships
(GATHER) [20] showed that five out of these ten genes fit into the
GO ontology category “transport” and/or “establishment of localization”
(data not shown). Additionally, the Allen Brain Atlas (http://www.
brain-map.org/) was used to determine the gene expression patterns
in cerebellum and Purkinje cells. For six out of ten genes, moderate to
high expression was seen in both granular cells and Purkinje cells
(data not shown). In contrast, UCHL1 and GJB1 showed almost no ex-
pression in Purkinje cells but were expressed in the granule cells. How-
ever, a more detailed analysis revealed a clear distinction between the
functions of these genes, as some operate in ion-transport, whereas
others are involved in synaptic transport or maintain the proper locali-
zation of glutamate transporters [21,22]. Thus, despite the discovery of
novel disease genes, more effort is required to reveal the pathways of
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model available yet for most ataxias that could be used to study the
causal molecular mechanism.
3. Genome-wide expression profiling in cerebellar ataxia
The application of expression profiling in neurodegenerative dis-
eases relies largely on the ability to use post-mortem brain material,
but this is only rarely available for rare cerebellar ataxias. Moreover,
the collected brain material often represents the end stage of disease,
so the resulting data is polluted with possible post-mortem effects,
and the brain tissue homogenates often contain a mixed population of
neurons that can each reflect a different pathophysiology. Single cell
laser microscopy isolating only the Purkinje cells from the cerebellum
may overcome this problem. Alternatively, blood or induced pluripotent
stem cells (iPS) can be used that may reflect the pathology in the cere-
bellum of adult cerebellar ataxia patients. In the absence of patient ma-
terial, in vivo or ex vivo models that express the disease genes and
mutations of interest can be used, and we will focus on studies per-
formed in humans and mice.
3.1. Gene expression profiling
To date, only three studies involving gene expression profiling
of human blood samples in cerebellar ataxia have been reported, and
one study using patient-derived iPS cells [23–26]. In blood from
Friedreich's ataxia (FRDA) patients, differential gene expression was
identified in genes expressed in the brain cortex and heart atria, as
well as in biological processes such as mitochondrial fatty acid beta-
oxidation, reactive oxygen species, and genotoxic stress response. This
finding was strengthened by direct evidence of mitochondrial and nu-
clear DNA damage in the blood [23]. Coppola et al. [24] and Ku et al.
[26] also detected dysregulation of genes involved in DNA repair in pe-
ripheral blood mononuclear cells (PBMCs) and iPS of cases, supporting
thehypothesis that DNA repair is important in the etiology of FRDA. Sur-
prisingly, the GO categories of genes that were differentially expressed
in iPS showed marked overlap with the GO categories obtained during
blood cell profiling, indicating that PBMCs can be a good alternative
when iPS are not available. In line with this, gene expression profiling
in lymphocytes of SCA28 patients revealed that the differentially
expressed genes clustered in well-defined functional categories such
as regulation of cell proliferation, regulation of programmed cell
death, and response to oxidative stress [25]. Functional validation
showed cellularmetabolic deficits including alterations inmitochondri-
al fission/fusion leading to markedly reduced cell viability in SCA28
lymphocytes, corroborating previous work in which haplo-
insufficiency of ALG3L2 led to mitochondria-mediated Purkinje cell
dark degeneration [27].
Six studies used cerebellar tissue of transgenic, knock-out or knock-
in mice for polyQ SCA types including SCA1, 2, 3 and 7 [28–33]. One of
these studies identified common transcriptional differences between
SCA1 and SCA7 in early disease stages, in addition to the many unique
differentially-expressed genes for each disease model [29]. Genes in-
volved in mRNA processing and chromatin were differentially
expressed for SCA1, whereas transcription factor binding and MHC
Class 1 proteins were identified for SCA7. Igfbp5, an insulin-like
growth-factor binding protein, was found to be themost significant dif-
ferentially expressed gene in both SCA1 and SCA7 cerebella that was
coupled with increased activation of the insulin growth-factor 1 recep-
tor, IGF1R. This work clearly showed that dysregulation of the IGF path-
way is a common pathogenic response in SCA1 and SCA7. Serra et al.
[28] used a strategy that led to the identification of a restricted set of
genes that were differentially expressed specific to the development
of SCA1. By comparing two non-ataxic transgenic SCA1 mouse lines
with ataxic SCA1 mice, only 9 genes were identified that were differen-
tially expressed in 5- and 12-week old ataxic mice. The functions ofthese genes revealed that the SCA1 Purkinje cell pathology could be
caused by alterations in glutamate signaling. Defects in glutamate sig-
naling due to mutations in glutamate transporters or receptors were
proven to cause Purkinje cell degeneration and ataxia in mice and
humans [34,35], demonstrating the importance of neuronal glutamate
homeostasis in cerebellar functioning.
Transcriptional dysregulation in SCA1 might be caused by a partial
loss-of-function of ataxin-1, as was proven by comparing transcription-
al defects in ataxin-1 knock-out mice versus ataxin-1 knock-in mice
[31], asmany of the shared transcriptional changes were acting in iden-
tical directions in both mousemodels. Notably, this work was unable to
confirm the outcomes of a previous study reporting transcriptional
changes in the ataxin-1 knock-out mice [36], with the exception of
some genes. However, this could be due to differences in genetic back-
ground of the two mouse strains, the differences in age of the mice,
and the type of microarray platform used. Ataxic staggerer mice that
carry a spontaneous loss-of-function mutation in the gene encoding
the transcription factor Rorα exhibit marked overlap in transcriptional
profiles with ataxin-1 knock-out mice [37], including genes involved
in calcium and glutamatergic signaling such as Itpr1 and Grm1, in
which loss-of-function mutations were reported, causing cerebellar
ataxia in humans and/or mice [38,39]. This raises the opportunity of
using the outcomes of transcriptional profiling to pinpoint novel disease
candidate genes because down-regulation of these genes could contrib-
ute to ataxic phenotypes. Mice expressing mutant ataxin-3 exhibited
reduced transcript levels of genes involved in glutamatergic neuro-
transmission, intracellular calcium signaling or MAP kinase pathways,
GABAA/B receptor subunits, heat shock proteins and transcription fac-
tors regulating neuronal survival and differentiation. Additionally,
upregulation of Bax, cyclin D1, and CDK5-p39 genes contributing to
neuronal death, were also observed mutant ataxin-3 mice [32].
Alterations in the expression of transcripts involved in glutamatergic
transmission, signal transduction, myelin formation, deubiquitination,
axon transport, neuronal differentiation or glial functions and heat
shock proteins were found to underlie the SCA7 pathology [33]. In
contrast, only FBXW8, encoding one of the subunits of the ubiquitin li-
gase complex, seems to play a specific role in the cerebellar pathology
of old ataxin-2 knock-in mice [30]. Depletion of soluble PABPC1 levels
by sequestering in the mutant ataxin-2 aggregates might result in im-
paired RNA processing as well as deficient protein synthesis in SCA2
[40]. These two themes are familiar in ataxia because of the disease
genes identified for SCA26 and SCA36, in which mutations in eEF2 and
NOP56 cause defects in protein synthesis and RNA processing, leading
to Purkinje cell loss and spinocerebellar ataxia [11,41].
One paper described the global gene expression profiles for various
tissues such as liver, skeletal muscle and heart from a hypomorphic
presymptomatic mouse model for FRDA [42]. The basic pattern of
transcriptional dysregulation that was seen in skeletal muscle and
liver matched their roles in energy metabolism including dysregulation
of the PPARγ/PGC1A pathway by marked downregulation of Pgc1a,
which is involved in mitochondrial biogenesis, energy substrate and
utilization, and oxidative metabolism [43]. Alteration in this path-
way may underlie the vulnerability of FRDA patients to diabetes as
it also regulates the insulin response. Additionally, in heart muscle, a
clear fiber-type switch and dysregulation of contractile proteins was
observed that could predispose patients to heart defects, as are seen in
many FRDA patients.
Recently, a comparative gene expression profiling experiment
was performed in Purkinje cells isolated from mouse cerebella using
laser capture microdissection from two different polyQ-disease mouse
models, namely Huntington's disease and SCA7 [44]. Thiswork revealed
shared molecular abnormalities in Purkinje cells from both mouse
models and indicated Pcp2-promoter repression as an early event in
the polyQ disease pathogenesis. Additionally, the expression of two
other genes, Aldoc and Plcb3, was also reduced in both models. This
data indicates that glycolysis and inositol 1,4,5-trisphosphate and 1,2-
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tioning. The 1,2-diacyl-glycerol activates protein kinase C gamma,
(PKCg), in which mutations were found to cause SCA14 [45]. This
is yet another example that highlights the strength of transcrip-
tional profiling in elucidating the underlying routes to cerebellar
neurodegeneration.3.2. miRNA profiling
Over the last decade, the role of microRNAs (miRNAs) in regulating
gene and protein expression has been established. Compelling evidence
has accumulated that these 21-nucleotide long, non-coding RNAs play
an important role in neuronal differentiation, as these molecules are
markedly differentially expressed during brain development and are in-
volved in dendritic spine formation and neurite outgrowth [46,47].
Schaefer et al. [48] demonstrated that the presence of miRNAs are
essential for the survival of post-mitotic neurons such as Purkinje
cells. Selective depletion of miRNAs in Purkinje cells by using condi-
tional knock-out mice lacking the major miRNA-generating enzyme,
Dicer, led to cerebellar neurodegeneration and ataxia. This data sug-
gested an essential function for miRNAs in the etiology of cerebellar
neurodegenerative disorders such as the spinocerebellar and cere-
bellar ataxias.
To date, only four studies have reported on the involvement of
specific miRNAs in the neuropathology of dominant spinocerebellar
ataxias, including SCA1 and SCA3 [49–52]. Direct binding of miR-
19, miR-101 and miR-130 to the 3′-UTR of ataxin-1 was found to
suppress the translation of the ataxin-1 protein [49]. Expression of
these miRNAs suppressed mutant ataxin-1-induced toxicity and
vice versa, knock-down of the miRNAs or mutagenesis of the
miRNA-binding sites in the 3′-UTR elevated ataxin-1 toxicity in cell
systems. Additionally, miRNA profiling of human brain samples re-
vealed that, among others, miR-144 was down regulated in SCA1
cerebella compared to healthy controls and miR-144 also suppresses
ataxin-1 expression similarly to miR-19, miR-101 and miR-130 [50].
Furthermore, miR-144 was strongly activated in the aging brains of
primates and Alzheimer's patients, which suggests that miR-144
could play a crucial role in post-transcriptional regulation of a
unique group of genes that are under selective miRNA control in
the brain during aging. A recent study performed miRNA profiling
in the cerebella of transgenic SCA1 mice of various ages but could
not confirm a major role for miR-19, miR-101, miR-130, or miR-144
in the developing SCA1 mouse neuropathology [51]. It suggested
that increased miR-150 levels indirectly modify SCA1 pathogenesis
via suppression of Vegfa levels in cerebellar neurons, indicating
that the outcomes of miRNA profiling studies are tissue- and
species-specific. miRNA profiling in the serum of SCA3 patients
showed that miR-25, miR-125b, miR-29a and miR-34b could be po-
tential biomarkers for SCA3 [52]. Both miR-25 and miR-125b were
predicted to bind to the 3′-UTR of the ataxin-3 gene andmay thereby
regulate ataxin-3 expression, whereas miR-29a andmiR-34b expres-
sion was most notably changed in SCA3 serum. miR-29a was already
reported to be down-regulated in Alzheimer's disease brains, where-
as miR-34b levels were significantly increased in the plasma of pre-
symptomatic Huntington's disease patients [53,54]. In FRDA blood
samples, profiling revealed elevated levels of miR-886-3p that corre-
lated with reduced frataxin protein levels, and knockdown of miR-
886-3p led to rescue of the suppressed frataxin levels in vitro [55].
Whether the actions of miR-886-3p on frataxin are direct or indirect
is not known.
Altogether, these studies showed that miRNAs are strong modifiers
of the cerebellar ataxia neuropathology and similar regulatory mecha-
nisms may exist for other neurodegenerative disorders. Additionally,
mutations in miRNA-binding sites or mutations in miRNAs might un-
derlie the group of genetically undiagnosed cerebellar ataxia patients.3.3. Methylation profiling
The epigeneticmachinery controlsmanyphysiological processes, in-
cluding brain development by regulating gene expression via DNA
methylation and deacetlylation/acetylation, and methylation of his-
tones remodeling the chromatin [56]. Epigenetic dysregulation under-
lies complex neurodegenerative disorders such as Alzheimer's and
Parkinson's disease [57,58], but no compelling evidence for this process
has been published for the monogenetic cerebellar ataxias. However,
very recently, a mutation in the DNA methylation factor, DNMT1, lead-
ing to global hypomethylation and genomic site-selective hypermethy-
lation, was reported to cause cerebellar ataxia, deafness and narcolepsy
syndrome [59]. Additionally, in many repeat expansion disorders, in-
cluding SCA1, a role for epigenetic alterations in pathogenesis has
been proposed [60]. In this case, epigenetic regulation might explain
the somatic repeat instability or may play a direct role in the toxic
gain of protein function. Moreover, particular DNAmethylation profiles
of the frataxin, FRDA disease gene, and its locus are not only correlated
with mutant frataxin expression, but also with the age of onset and dis-
ease severity [61].
Only one study took the opportunity to study the genome-wide
transcriptional and epigenetic changes in early onset polyQ-disease
in parallel, using the HD-82Q mouse model [62], which could be trans-
lational for other repeat expansion disorders, including some of the
spinocerebellar ataxias. In this study, many hypoacetylated loci were
detected for H3K9,14 and H4K12 in hippocampal chromatin using
CHIP-seq, and correlated with only a subset of transcriptional dysregu-
lated genes. However, these dysregulated genes were consistently
detected in the different brain areas of a Huntington's disease mouse
model and tissue from patients, and are thus likely to play a role in
thedisease pathology. The functional categories of these geneswere sig-
nificantly enriched for the GO terms synaptic vesicle, synapse, postsyn-
aptic membrane, and calcium ion binding.
Given the limited number of publications, methylation profiling
using CHIP-seq clearly still needs to be explored for the insights it can
yield into neurodegenerative disorders, including cerebellar ataxias.
4. Genomewide geneticmodifier screens in cerebellar ataxiamodels
Genetic modifiers play an important role in neurodegenerative
disorders, influencing the age of onset, progression and severity of the
disease. Identifying such modifiers would greatly improve our under-
standing of the underlying pathology of the disease and could lead to
novel therapeutic targets. For ataxia, most modifier screens are per-
formed for polyQ ataxias (SCA 1, 2, 3, 6, 7 and 17), since the polyQ dis-
orders form the largest group within the neurodegenerative field, and
includes Huntington's disease, the most common hereditary neurode-
generative disorder. Because these disorders are all caused by a gluta-
mine expansion in the disease gene, they are thought to be linked on
a molecular level. Therefore, modifier genes found for one of the
polyQ disorders are likely to have a modifying function in one or all of
the other polyQ diseases.
For ataxia, a number of modifiers have been identified in Drosophila
melanogaster [63–69]. The fruit fly is widely used as a model for human
disorders; its short generation time andwell described genetics make it
a powerful tool to study neurodegenerative disorders, since the genetic
pathways involved in development and disease are strongly conserved
between Drosophila and mammals. Furthermore, the flies are easily
genetically altered to mimic human disease and to screen for genetic
modifiers. Screening for these modifiers is performed by crossing
disease-mimicking flies withflies containing P or EP element insertions,
followed by screening of the F1 progeny for enhanced or attenuated
phenotypes.
Genome-wide modifier screens usually yield a high number of
modifier genes, which then have to be identified, categorized and vali-
dated. Fernandez-Funez et al. [63] reported performing two modifier
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Some of these modifier genes – functioning in the protein folding/heat
shock response or ubiquitin-proteolytic pathways – were already
known to modify polyglutamine-induced disease. Others were not pre-
viously known tomodify polyQ disorders, such as genes involved in ox-
idative and/or chemical stress, the nuclear pore complex, RNA
processing, and transcriptional regulation. Because genome-wide
screens are costly and time consuming, and give a relatively low yield,
a targeted approach may bemore suitable. Furthermore, it is important
to validate the present findings in a separate model to demonstrate the
legitimacy of the screen.
Latouche et al. [67] crossed a flymodel for SCA7with 36 different fly
lines characterized by the enhancement or disruption of genes that
could, by their function, modulate the SCA7 phenotype. Two genes
previously identified as modifiers of SCA1 (Ppd3 and mub) enhanced
the SCA7 phenotype and expression of mub in adult neurons signifi-
cantly reduced lifespan of the SCA7 files [63,67]. Interestingly, reduced
expression of ATXN2, the causative gene for SCA2 when mutated,
strongly suppressed the SCA7 phenotype. This further emphasizes the
need to validate the results of a genetic modifier screen in a second
model, such as a relevant cell or animal model, as presented by Park
and co-workers [68].
A second screening technique uses RNA interference to knock
down a single gene in flies. Model flies are crossed with flies expressing
an RNAi construct, which produces a small interfering RNA molecule
targeted to a specific gene, followed by screening of the F1 progeny
for enhanced or suppressed phenotypes [69]. SCA17 is caused by a
polyQ expansion in the human TATA-box-binding protein (hTBP) [70].
Because hTBP is a transcription factor, a microarray analysis was per-
formed to study the resulting dysregulation induced by mutant hTBP
[69]. This showed that Q/N-rich transcription factors greatly contribute
to the transcriptional dysregulation induced by hTBP80Q. One of these
Q/N-rich transcription factors, Su(H), a nuclear component of Notch sig-
naling, was identified as a key candidate, since RNAi knock-down of
Su(H) enhanced the SCA17 phenotype significantly via a direct interac-
tion with hTBP. Conversely, increased expression of Su(H) could rescue
the SCA17 phenotype, indicating that the Su(H) levels control transcrip-Fig. 1. Diagram illustrating the overlap of pathways identified in gene–gene interaction networ
conventional SCA types (see Table 1 for more details).tion regulation and thereby the SCA17 disease phenotype. This work
clearly showed the importance of functional validation of findings
from RNAi modifier screens. However, further validation in a more bio-
logically relevant system (e.g. mouse) should still be performed.
Park et al. [68] performed a cross-species screen in Drosophila,
human cells and mice, specifically targeting human kinases in order
to identify kinases that can modify ATXN1 toxicity. This is based on
previous work in which they showed that phosphorylation of ATXN1
regulates ATXN1 protein stability, and that both factors play a crucial
role in the development of SCA1 [71]. In a human cell line, all human
kinase and kinase-like genes were targeted with short interfering
RNAs (siRNAs) to determine the effect on ATXN1 levels. To validate
the findings of this screen, siRNAs that changed ATXN1 levels were
transfected individually in ATXN1(82Q) expressing cells yielding 50
siRNAs for 45 genes. In parallel, a genetic screen targeted at kinases
identified 49 genes that suppressed ATXN1(82Q) toxicity in a Drosoph-
ila SCA1 model. Both screens were then combined, and revealed 10
human kinases that diminish ATXN1 levels and ATXN1-induced toxici-
ty. A network analysis showed that the MAPK pathway is highly
enriched in both screens, because IGF1R, various MEKs, ERK1 and
ERK2 were identified. Reduced activity of the MAPK pathway dimin-
ished SCA1 motor dysfunction in flies by modulation of ATXN1 levels.
Moreover, ATXN1 levels could also be decreased pharmacologically by
PD184352 (a MEK1/2 inhibitor), GW5704 (a RAF1 inhibitor), H89 and
Ro-31-8220 (MSK1 inhibitors) in human cells.
The work of Park et al. [64] showed that identification of modifier
genes is not enough to make progress in understanding the disease eti-
ology of SCA1. Modifier genes that suppress the disease phenotype
should be studied more closely to validate the genes as modifiers, to
determine whether the identified genes can be linked via one or two
pathways and whether a stellar protein of the pathway can be devel-
oped as a drug target.
5. Generation of a cerebellar ataxia network
To get a clearer and more accurate picture of the common disease
pathways, we generated a gene–gene interaction network based onks derived from all cerebellar ataxias with or without FRDA, polyglutamine SCA types, and
2035C.J.L.M. Smeets, D.S. Verbeek / Biochimica et Biophysica Acta 1842 (2014) 2030–2038the co-expression of genes based on a total of approximately 80,000
microarrays from Gene Expression Omnibus (see more at: http://
genenetwork.nl:8080/GeneNetwork/#!) with novel cerebellar ataxia
genes identified via exome sequencing and significant, previouslyFig. 2. Cerebellar ataxia gene–gene interaction network including conventional SCA types, poly
total of approximately 80,000 microarrays from the Gene Expression Omnibus. The interactio
yellow-to-green genes, indicating an increasing number of connections, are the co-expressed g
The p-value thresholdwas set to 1 × 10−10. The boxes indicate the putative biological pathways
genes within the indicated clusters.reported, differentially expressed genes or modifier genes of known
cerebellar ataxia genes (see Supplementary Table 1; the software
used for generation of the network – GeneNetwork – was written by
J. Karjalainen and Dr. L. Franke, UMCG, and is unpublished). When weglutamine SCA types and FRDA (see Table 1 for more details). This network is based on a
ns between the genes are based on co-expression. The red genes are the input genes, the
enes. This network helps to predict gene function and can reveal the underlying pathway.
identified using the programGATHER by analyzing the gene ontology of the co-expressed
Table 2
List of input genes and corresponding predicted pathway using GATHER.
Gene names Predicted pathway
APP, PDIA3, SEC61A1, CALR Protein folding & transport
ATF5, CBS, SLC7A1 Amino acid metabolism
DNMT1, GAS2L3, PBK, SPAG5, LMNB1, CKAP5 Cell cycle & proliferation
COL9A3, COL9A2 Phosphate & ion transport
TTC14, SFPQ, PABPNA mRNA transport
DUSP1, KLF4, NR4A1, RGS2, ADAMTS1 Regulation of transcription
BAG3, HSPA1B, CHORDC1 Protein folding
NINJ1, BIRC3, WDFC2 Apoptosis
MOG, MAG, MOBP, MBP, NINJ2, CDK18,
ENPP2, TF, TTR, GJB1, NRGN, C6ORF25,




HPCA, CBLN2, NGEF, SIX3, KIF5A, SYNPR, CHL1,
DRD2, GRM1, PLP1, SLC12A2, CPNE6, RASAl1,
ITPKA, RTN4Rm NECAB3, CHL1, NRSN1,
AP3B2 SYNGR3, SLC17A6, CHN2, SEZ6,
GNG13, KCNIP4, RTN1, NPTXC1, GABRD,
PRKCG, PENK, RSG4
Synaptic transmission
LILRA2, CTSS, CSF1R, EMR1, ADORA3, SLA,
GAL3ST4, LGMN, PLAG7, CYP27A1, ITGAL,
ACP5, APOE, PLD3, ATP2A3, BLK, LEF1,
CREG1, NKG7, HS3ST2, PPP2R2B, PRKCH,
EOMES, PTPN4, FYN, GIMAP5, GIMAP6,
EBF1, EGFL7, RAMP2, ADCY4, EPAS1, ACE,
COL18A1, AGRN, PLXDC1, LGR5, FXYD6,
Cell communication &
defense/immune response
BCL11A, MCTP2, PIM2, ABCA1
CAP2, MYBPC3, CACNA1C, FHOD3
Muscle contraction
SCARB1, ALDOC, DHCR24, VEGFA, AGRP Hexose & carbohydrate
metabolism
2036 C.J.L.M. Smeets, D.S. Verbeek / Biochimica et Biophysica Acta 1842 (2014) 2030–2038generated a network for only the conventional SCA types (see Table 1),
it showed that many of these genes connect directly or indirectly with
each other and act in pathways such asneurogenesis, synaptic transmis-
sion, cell communication, defense/immune response, and protein fold-
ing (Figs. 1 and 2, and Table 2). Many of these pathways are known to
be involved in cerebellar ataxia, with the exception of the defense/im-
mune response [6,7,72].
Upon further refining the network by adding the gene list related to
the polyQ SCA types to the conventional SCA types (all SCA types with-
out FRDA), more known pathways emerged including regulation of
transcription, cell cycle and proliferation, and RNA splicing. Pathways
not previously reported also emerged including hexose/carbohydrate
metabolism,muscle contraction, and regulation of bodyfluids and coag-
ulation (Figs. 1 and 2). How these newly identified pathways contribute
to the etiology of cerebellar ataxia is still unknown, and we can only
speculate about the involvement of the hexose/carbohydrate metabo-
lism and regulation of body fluids and coagulation in cerebellar ataxia.
Brain energy metabolism, for instance, might play an important role in
activation of glutamate receptors and the induction of excitotoxicity
leading to neuronal cell death, or increased mitochondrial hexokinase
II activity can prevent cell death in Parkinson's disease-related neuronal
cultures [73,74]. Coagulation inhibitors might treat seizures and epilep-
sy, and various coagulation inhibitors are in the list of drugs in devel-
opment for neurodegenerative diseases [75,76]. The putative role of
muscle in cerebellar ataxia is shown by muscle Q10 deficiency causing
familiar cerebellar ataxia and seizures [77]. Additionally, supplements
of Q10 improvedmuscle strength and the ataxia, and reduced the sever-
ity of the seizures, and FRDAmice exhibit mitochondrial impairment of
their muscles [78]. Upon adding the FRDA-related genes (all cerebellar
ataxias; Fig. 2) to the network, two extra pathways emerged: protein
synthesis and mRNA transport (Fig. 1 and Table 2). Notably, no marked
DNA damage response, mitochondrial fatty acid beta-oxidation, and/or
reactive oxygen species was detected, whereas DNA metabolism and
steroid and lipidmetabolismwere detected in an FRDA specific network
(data not shown).Altogether, this network analysis clearly demonstrates that there are
common routes to cerebellar neurodegeneration and ataxia, and it high-
lights novel molecular mechanisms, including muscle contraction and
coagulation, as potential candidates for therapeutic intervention.
6. Future prospects
The work summarized in this review revealed a marked increase
in the usage of unbiased genome-wide approaches over the last
five years to reveal novel disease genes and the underlying molecu-
lar mechanisms of cerebellar ataxias. In the absence of high-quality,
post-mortem material, appropriate disease models, including patient-
derived iPS cells, Drosophila melanogaster, and transgenic, knock-in
and knock-out mice, have proven to be valuable in understanding the
underlying disease mechanisms. Although conventional SCA types cur-
rently outnumber the repeat-expansion SCAs, the main focus of re-
search is still on the polyQ-SCA types, including SCA1 and SCA3,
yielding a potentially biased view of the underlying biological pathways
that lead to cerebellar ataxia. To overcome this bias, major investments
are needed in the generation of disease models for conventional SCA
types, as these SCA types seem to be caused by a select group of path-
ways pointing towards deficits in cell communication, proliferation,
and synaptic transmission.Different genetic backgrounds can also intro-
duce a bias in the phenotypes of fly and mouse models [79,80], and
should always be considered. Additionally, the presence of geneticmod-
ifiers is also reflected in the variance in age of onset and disease severity
in polyglutamine SCA types including RAI1 and CACNA1Amodifying the
age of onset of SCA2 [81–83]. Nevertheless, the use of functional geno-
mic approaches, including whole exome sequencing, genome-wide
gene expression profiling, miRNA profiling, epigenetic profiling, and ge-
netic modifier screens have already contributed new knowledge and
will continue to provide insights that improve our understanding of
the pathology of cerebellar ataxia. This all may lead to the identification
of targets opening doors for therapeutic intervention that could prevent
disease progression in cerebellar ataxia patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.04.004.
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